A video summary of the latest infectious disease headlines.
Hello and welcome to Contagion. Heart disease continues to be the leading cause of death in the United States. And for those with heart disease living in New York City during the coronavirus 2019 (COVID-19) outbreak, several factors have led to more people needing out-of-hospitalization resuscitations.
During the pandemic, New York City has seen a three-fold increase in the number of out-of-hospitalization cardiac arrest resuscitations, according to a new study. And in comparison to previous years, patients were more likely to have specific comorbidities and less likely to be of white ethnicities.
In other news, Nabriva Therapeutics announced it received a complete response letter letter from the US Food and Drug Agency regarding its anti-infective agent fosfomycin. The company is seeking FDA approval for injection for complicated urinary tract infections (cUTI).
In the letter, the FDA cited an inability to conduct inspections at the company’s manufacturing facilities due to coronavirus 2019 (COVID-19)-related travel restrictions. The FDA clarified that it was not looking for any additional data related to fosfomycin’s efficacy or safety.
Few patients in intensive care units undergo antimicrobial de-escalation for treatment of bacterial infections, according to a recent study, which also noted that the antimicrobial stewardship strategy did not negatively affect clinical cure results.
The study, published in Intensive Care Medicine, evaluated 1495 adult patients empirical antimicrobial therapy for bacterial infection in 152 intensive care units to determine how often antimicrobial de-escalation is performed and to estimate how it effects clinical cure. For results, and more on the latest infectious disease news, visit Contagionlive.com. For Contagion, I’m Grant Gallagher, thanks for watching.